Filtered By:
Specialty: Research
Condition: Bleeding
This page shows you your search results in order of relevance. This is page number 4.
Order by Relevance | Date
Total 130 results found since Jan 2013.
FDA-Catalyst-Using FDA's Sentinel Initiative for large-scale pragmatic randomized trials: Approach and lessons learned during the planning phase of the first trial.
CONCLUSION:: Sentinel infrastructure generated preliminary data that supported planning and implementation of a large pragmatic trial embedded in health plans. This planning identified unanticipated challenges that must be addressed in similar trials.
PMID: 30445835 [PubMed - as supplied by publisher]
Source: Clinical Trials - November 16, 2018 Category: Research Authors: Cocoros NM, Pokorney SD, Haynes K, Garcia C, Al-Khalidi HR, Al-Khatib SM, Archdeacon P, Goldsack JC, Harkins T, Lin ND, Martin D, McCall D, Nair V, Parlett L, Temple R, McMahill-Walraven C, Granger CB, Platt R Tags: Clin Trials Source Type: research
Safety and Efficacy of Triple Antithrombotic Therapy with Dabigatran versus Vitamin K Antagonist in Atrial Fibrillation Patients: A Pilot Study.
Conclusion: Dabigatran at the dose used for stroke prevention appears safer than VKA and maintains a similar efficacy profile, when used with DAPT, in AF patients who have undergone PCI with stenting for ACS.
PMID: 30895193 [PubMed - in process]
Source: Biomed Res - March 22, 2019 Category: Research Authors: Russo V, Rago A, Proietti R, Attena E, Rainone C, Crisci M, Papa AA, Calabrò P, D'Onofrio A, Golino P, Nigro G Tags: Biomed Res Int Source Type: research
Methodologies for pragmatic and efficient assessment of benefits and harms: Application to the SOCRATES trial.
CONCLUSION: Ordinal outcomes can improve efficiency through required pre-specification, careful construction, and analyses. Greater pragmatism can be obtained by composing outcomes within patients. Desirability of outcome ranking provides a global assessment of the benefits and harms that more closely reflect the experience of patients. The desirability of outcome ranking probability, the proportion in favor of treatment, the win ratio, and partial credit can more optimally inform patient treatment, enhance the understanding of the totality of intervention effects on patients, and potentially provide efficiencies over stan...
Source: Clinical Trials - July 14, 2020 Category: Research Authors: Evans SR, Knutsson M, Amarenco P, Albers GW, Bath PM, Denison H, Ladenvall P, Jonasson J, Easton JD, Minematsu K, Molina CA, Wang Y, Wong KL, Johnston SC Tags: Clin Trials Source Type: research
Real-world effectiveness and safety of rivaroxaban versus warfarin among non-valvular atrial fibrillation patients with obesity in a US population
CONCLUSIONS: These results suggest that rivaroxaban is an effective and safe treatment option among NVAF patients with obesity in a commercially-insured US population.PMID:33733969 | DOI:10.1080/03007995.2021.1901223
Source: Current Medical Research and Opinion - March 18, 2021 Category: Research Authors: Jeffrey S Berger Fran çois Laliberté Akshay Kharat Dominique Lejeune Kenneth Todd Moore Young Jung Patrick Lefebvre Veronica Ashton Source Type: research
Clinical Relevance of Anticoagulation and Dual Antiplatelet Therapy to the Outcomes of Patients With Atrial Fibrillation and Recent Percutaneous Coronary Intervention With Stent.
CONCLUSIONS: TT, DT and DAPT displayed similar efficacy and safety. Although the superiority of OAC vs. DAPT for stroke prevention in AF patients has been demonstrated by previous randomized trials, a smaller frequency of high thromboembolic risks' features in DAPT group of the present study may have prevented the observation of a higher incidence of ischemic stroke in this group.
PMID: 26767085 [PubMed]
Source: Clin Med Res - January 18, 2016 Category: Research Authors: De Vecchis R, Cantatrione C, Mazzei D Tags: J Clin Med Res Source Type: research
Real-World Analysis of more than 44,000 Patients Reinforces Safety and Effectiveness of Pradaxa® in Routine Clinical Care
• New data show Pradaxa® reduced stroke risk and major bleeding compared to warfarin in patients with non-valvular atrial fibrillation1 • Pradaxa® was associated with 28% and 26% reductions in stroke risk and major bleeding events compared to warfarin, respectively1
Source: Boehringer Ingelheim Corporate News - November 9, 2015 Category: Research Source Type: news
Comparison of treatment outcomes of ticagrelor and clopidogrel among patients undergoing percutaneous coronary intervention: A meta-analysis
SummaryWe performed a meta-analysis of randomized controlled trials (RCTs) to investigate the efficacy and safety of ticagrelor (TIC) vs. clopidogrel (CLO) in patients undergoing percutaneous coronary intervention (PCI). In Jun 2016, a literature search was started and all the studies were conducted from 2010 to 2015. We systematically searched the literature through the MEDLINE database, Cochrane library, and EMBASE database. Quality assessments were evaluated with Jadad quality scale. Data were extracted considering the characteristics of efficacy and safety designs. Six RCTs enrolling 26 244 participants and satisfying ...
Source: Journal of Huazhong University of Science and Technology -- Medical Sciences -- - October 1, 2017 Category: Research Source Type: research
Perioperative Management of Antiplatelet Therapy in Patients With History of Coronary Artery Disease Undergoing Surgery for Esophageal Cancer: A Single-center Experience
Conclusion: It is a reasonable approach to discontinue antiplatelet therapy for more than 7 days before surgery, especially in such a population of patients with esophageal cancer that require complex operations with high bleeding risk.
Source: In Vivo - February 25, 2019 Category: Research Authors: SCHIZAS, D., THEOCHARI, N. A., THEOCHARI, C. A., KOKKINIDIS, D. G., DOMI, V., MPAILI, E., JONNALAGADDA, A. K., KAPELOUZOU, A., BAKOPOULOS, A., LIAKAKOS, T. Tags: Clinical Studies Source Type: research
Genotype-guided antiplatelet therapy compared with conventional therapy for patients with acute coronary syndromes: a systematic review and meta-analysis.
Conclusions: Genotype-guided strategies could reduce the rates of cardiovascular events without increasing bleeding events compared with conventional treatment in ACS. Future multi-center genotype-based RCTs are required to confirm these findings.
PMID: 31215825 [PubMed - as supplied by publisher]
Source: Biomarkers - June 21, 2019 Category: Research Tags: Biomarkers Source Type: research
Real-life behaviour of direct oral anticoagulants in a Spanish cohort with nonvalvular atrial fibrillation: Refase Registry.
CONCLUSION: Our results of safety and efficacy are very similar to those of other previously published national registries. There were no differences among the different types of DOAC regarding outcomes. However, it was found that people taking the adjusted dose of the drug seemed to have a higher risk of death. A non-negligible proportion of patients received DOAC doses inconsistent with labelling (mostly underdose).
PMID: 31335222 [PubMed - as supplied by publisher]
Source: Current Medical Research and Opinion - July 25, 2019 Category: Research Tags: Curr Med Res Opin Source Type: research
Efficacy and Safety of Antiplatelet Therapy Plus Xa Factor Inhibitors in Patients with Coronary Heart Disease: A Meta-Analysis.
CONCLUSIONS Antiplatelet therapy plus Xa factor inhibitors in patients with coronary artery disease was effective, which could reduce the risk of ischemic composite endpoints, all-cause mortality, myocardial infarction, and ischemic stroke. However, it could significantly increase risk of bleeding in terms of safety.
PMID: 31335859 [PubMed - in process]
Source: Medical Science Monitor - July 25, 2019 Category: Research Tags: Med Sci Monit Source Type: research
Ablation Versus Medical Therapy for Atrial Fibrillation in the Elderly: A Propensity Score-Matched Comparison.
CONCLUSIONS In this propensity-matched elderly sample, ablation therapy was associated with lower risk of composite outcome consisting of all-cause death, non-fatal stroke, and peripheral embolism, and therefore might be an alternative to conservative therapy.
PMID: 31866666 [PubMed - in process]
Source: Medical Science Monitor - December 25, 2019 Category: Research Tags: Med Sci Monit Source Type: research
